Market Research Logo

Alnylam Pharmaceuticals, Inc. - Product Pipeline Review - 2016

Alnylam Pharmaceuticals, Inc. - Product Pipeline Review - 2016

Summary

Global Markets Direct’s, ‘Alnylam Pharmaceuticals, Inc. - Product Pipeline Review, 2016’, provides an overview of the Alnylam Pharmaceuticals, Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Alnylam Pharmaceuticals, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Alnylam Pharmaceuticals, Inc.
  • The report provides overview of Alnylam Pharmaceuticals, Inc. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Alnylam Pharmaceuticals, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Alnylam Pharmaceuticals, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
  • Evaluate Alnylam Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Alnylam Pharmaceuticals, Inc.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Alnylam Pharmaceuticals, Inc.’s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Alnylam Pharmaceuticals, Inc. Snapshot
Alnylam Pharmaceuticals, Inc. Overview
Key Information
Key Facts
Alnylam Pharmaceuticals, Inc. - Research and Development Overview
Key Therapeutic Areas
Alnylam Pharmaceuticals, Inc. - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Partnered Products
Partnered Products/Combination Treatment Modalities
Alnylam Pharmaceuticals, Inc. - Pipeline Products Glance
Alnylam Pharmaceuticals, Inc. - Late Stage Pipeline Products
Phase III Products/Combination Treatment Modalities
Alnylam Pharmaceuticals, Inc. - Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Alnylam Pharmaceuticals, Inc. - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Alnylam Pharmaceuticals, Inc. - Drug Profiles
patisiran
Product Description
Mechanism of Action
R&D Progress
revusiran
Product Description
Mechanism of Action
R&D Progress
ALN-PCSsc
Product Description
Mechanism of Action
R&D Progress
fitusiran
Product Description
Mechanism of Action
R&D Progress
ALN-AAT
Product Description
Mechanism of Action
R&D Progress
ALN-CC5
Product Description
Mechanism of Action
R&D Progress
ALN-GO1
Product Description
Mechanism of Action
R&D Progress
ALN-HBV
Product Description
Mechanism of Action
R&D Progress
ALN-AS1
Product Description
Mechanism of Action
R&D Progress
ALN-TTRsc02
Product Description
Mechanism of Action
R&D Progress
ALN-VSP
Product Description
Mechanism of Action
R&D Progress
ALN-AC3
Product Description
Mechanism of Action
R&D Progress
ALN-AGT
Product Description
Mechanism of Action
R&D Progress
ALN-ANG
Product Description
Mechanism of Action
R&D Progress
ALN-PDL
Product Description
Mechanism of Action
R&D Progress
ALN-TMP
Product Description
Mechanism of Action
R&D Progress
Antisense RNAi Oligonucleotide to Target Cyclin-Dependent Kinase Inhibitor 1 for Bladder Cancer
Product Description
Mechanism of Action
R&D Progress
Cellular Immunotherapy for Oncology and Viral Infections
Product Description
Mechanism of Action
R&D Progress
ALN-HDV
Product Description
Mechanism of Action
R&D Progress
RNAi Oligonucleotide for Undisclosed Indication
Product Description
Mechanism of Action
R&D Progress
RNAi Oligonucleotides for Genetic Diseases
Product Description
Mechanism of Action
R&D Progress
RNAi Oligonucleotides for Hepatic Infections
Product Description
Mechanism of Action
R&D Progress
RNAi Oligonucleotides for NASH, Cardiovascular and Metabolic Disorders
Product Description
Mechanism of Action
R&D Progress
Alnylam Pharmaceuticals, Inc. - Pipeline Analysis
Alnylam Pharmaceuticals, Inc. - Pipeline Products by Target
Alnylam Pharmaceuticals, Inc. - Pipeline Products by Route of Administration
Alnylam Pharmaceuticals, Inc. - Pipeline Products by Molecule Type
Alnylam Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action
Alnylam Pharmaceuticals, Inc. - Recent Pipeline Updates
Alnylam Pharmaceuticals, Inc. - Dormant Projects
Alnylam Pharmaceuticals, Inc. - Company Statement
Alnylam Pharmaceuticals, Inc. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Alnylam Pharmaceuticals, Inc., Key Information
Alnylam Pharmaceuticals, Inc., Key Facts
Alnylam Pharmaceuticals, Inc. - Pipeline by Indication, 2016
Alnylam Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016
Alnylam Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016
Alnylam Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2016
Alnylam Pharmaceuticals, Inc. - Partnered Products/ Combination Treatment Modalities, 2016
Alnylam Pharmaceuticals, Inc. - Phase III, 2016
Alnylam Pharmaceuticals, Inc. - Phase II, 2016
Alnylam Pharmaceuticals, Inc. - Phase I, 2016
Alnylam Pharmaceuticals, Inc. - Preclinical, 2016
Alnylam Pharmaceuticals, Inc. - Discovery, 2016
Alnylam Pharmaceuticals, Inc. - Pipeline by Target, 2016
Alnylam Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2016
Alnylam Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016
Alnylam Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2016
Alnylam Pharmaceuticals, Inc. - Recent Pipeline Updates, 2016
Alnylam Pharmaceuticals, Inc. - Dormant Developmental Projects,2016
Alnylam Pharmaceuticals, Inc., Subsidiaries
ist of Figures
Alnylam Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2016
Alnylam Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016
Alnylam Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016
Alnylam Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2016
Alnylam Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2016
Alnylam Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016
Alnylam Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report